SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin clinical trials with its drug candidate HE3286 for the treatment of diseases of inflammation. Assuming clearance of the IND by the FDA, Hollis-Eden plans to initiate a Phase I/II clinical trial of HE3286 in rheumatoid arthritis (RA) patients during the fourth quarter of 2007. Additionally, upon clearance of this IND Hollis-Eden may also consider commencing exploratory studies in the fourth quarter of 2007 to evaluate HE3286 in one or more acute inflammatory conditions, where evidence of activity against well-accepted clinical endpoints could potentially be generated with 28-day dosing.
